ExosomePlus, established in 2018, focuses on advancing the field of extracellular vesicles (EVs) for regenerative therapy, addressing challenges in the pharmaceutical industry. The company leverages its extensive research and development experience, which includes over a decade of directed work in exosome applications, resulting in more than 10 patents. By forming strategic partnerships, ExosomePlus aims to integrate high-purity exosomes into therapeutic targeting, enhancing efficacy and versatility in medical science.

One of the key technologies developed by ExosomePlus is ExoCope™, an advanced nanoparticle tracking analysis (NTA) system designed for the isolation and characterization of single extracellular vesicles. This innovative system utilizes a four-color laser engine to provide comprehensive six-dimensional data for each EV, including diameter and fluorescence intensity. This capability allows researchers to analyze subpopulation distributions within heterogeneous EV samples and quantify specific antigens, facilitating a deeper understanding of EV characteristics and their potential applications in therapeutic contexts.

South Korea

Exosome Plus was founded in 2018to drive an extracellular vesicle (EV) revolution, bringing the best EV isolation and characterization platform in the field of regenerative therapy to bear on research wide challenges faced by pharmaceutics industry.

Exosome Plus

Company Details